For decades, sleep has been regarded as a restorative biological process, but its disruption in later life may do more than impair cognition or mood — it may accelerate the molecular machinery of aging itself. Evidence now suggests that treating chronic insomnia with a structured psychological intervention could partially reverse that acceleration, with measurable changes at the epigenetic level.
This secondary analysis, embedded within a randomized controlled trial of adults aged 60 and older in Los Angeles, compared cognitive behavioral therapy for insomnia (CBT-I) against sleep education therapy (SET) — an active control designed to limit placebo effects. Biological aging was quantified using three DNA methylation-derived epigenetic clocks: DunedinPACE, which tracks the pace of physiological deterioration; GrimAge, which predicts mortality risk; and PCPhenoAge, a principal-component version of the phenotypic age clock. Blood was drawn at baseline and again at 20 to 39 months post-enrollment (winsorized to 30 months), yielding paired epigenetic data for 47 CBT-I participants with a mean age of 69.5 years.
The results position CBT-I as more than a symptomatic remedy for poor sleep. Epigenetic clocks are now among the most validated proxies for biological rather than chronological age, and their responsiveness to a behavioral intervention — not a drug or supplement — is noteworthy. The finding adds to a growing body of evidence linking sleep architecture to hallmarks of aging including inflammation, telomere attrition, and cellular senescence. Critically, however, this is a single-site, relatively small secondary analysis, and the SET comparator, while active, may still have underdelivered relative to CBT-I on purely behavioral engagement. The absence of a no-treatment control also limits causal inference about sleep education's independent effect. Nevertheless, for clinicians and health-conscious adults alike, the suggestion that a first-line, non-pharmacological insomnia treatment may decelerate epigenetic aging in older adults represents a potentially paradigm-shifting, if preliminary, signal worth replicating in larger multicenter trials.
